Company news

Monopar Therapeutics Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma Pipeline

May 8, 2024

Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting

April 17, 2024

Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings

April 15, 2024

Monopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer Patients

April 9, 2024

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

March 27, 2024

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

March 4, 2024

Monopar Provides Update on MNPR-101-Zr Radiopharma Clinical Trial

February 26, 2024

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

February 21, 2024

Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

February 19, 2024

Monopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent Developments

November 8, 2023

Monopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting

October 31, 2023

Monopar to Participate in the Roth MKM 2023 Healthcare Opportunities Conference

October 9, 2023

Monopar to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

September 4, 2023

Monopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent Developments

August 9, 2023

Monopar Provides Encouraging Camsirubicin Clinical Data Update

August 7, 2023

Monopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore

July 10, 2023

Monopar to Participate in the Radiopharma Forum by the Lake 2023

June 20, 2023

Monopar to Participate in the Maxim Group’s Healthcare Virtual Conference

June 13, 2023

Monopar Announces Encouraging Camsirubicin Phase 1b Trial Update

May 31, 2023

Monopar Therapeutics Reports First Quarter 2023 Financial Results and Recent Developments

May 10, 2023

Monopar to Present at the Jefferies Radiopharma Innovation Summit

March 27, 2023

Monopar Announces Result of Interim Analysis of Phase 2b/3 VOICE Trial Evaluating Validive for Severe Oral Mucositis

March 26, 2023

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Developments

March 22, 2023

Monopar to Present at the 35th Annual Roth Conference

March 6, 2023

Monopar and NorthStar Announce Expanded Radiopharma Program, Positive Preclinical Results, and Visibility Toward Human Trials

February 26, 2023

Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin

February 13, 2023

Monopar Announces Projected Timeline of Upcoming Q1 2023 Data Events for Validive, Camsirubicin, and MNPR-101 RIT

January 25, 2023

Monopar Announces Successful Advancement of Camsirubicin Phase 1b Clinical Trial Past Fourth Cohort, Escalates Next to 650mg/m2

January 17, 2023

Monopar Announces Promising MNPR-202 Data from Ongoing National University of Singapore Collaboration

December 11, 2022

Monopar Announces Encouraging Clinical Data from Ongoing Camsirubicin Phase 1b Trial

November 15, 2022

Monopar Therapeutics Reports Third Quarter 2022 Financial Results and Recent Program Developments

November 9, 2022

Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202

October 26, 2022

Monopar Announces Presentation Selected for 2022 American Society of Hematology (ASH) 64th Annual Meeting

October 18, 2022

Monopar Announces Presentation Selected for 2022 Connective Tissue Oncology Society (CTOS) Annual Meeting

October 11, 2022

Monopar Announces Completion of Phase 2b Enrollment and Commencement of Phase 3 Enrollment in its VOICE Trial for Severe Oral Mucositis

October 4, 2022

Monopar to Present at Roth Inaugural Healthcare Opportunities Conference

September 27, 2022

Monopar Therapeutics Reports Second Quarter 2022 Financial Results and Recent Program Developments

August 10, 2022

Monopar Therapeutics Reports First Quarter 2022 Financial Results and Recent Program Developments

May 11, 2022

Monopar Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Developments

March 23, 2022

Monopar to Present at the 34th Annual Roth Conference and Maxim’s 2022 Virtual Growth Conference

March 7, 2022

Monopar Announces Clinical and Preclinical Program Updates

February 14, 2022

Monopar to Present at the H.C. Wainwright BioConnect Conference

January 6, 2022

Monopar Advances Dosing of Camsirubicin to Higher Level Than Tested In Any Previous Clinical Trial

December 7, 2021

Monopar Therapeutics Reports Third Quarter 2021 Financial Results and Recent Clinical Developments

November 11, 2021

Monopar Announces First Patient Dosed in Phase 1b Trial Evaluating Camsirubicin for the Treatment of Advanced Soft Tissue Sarcoma

October 26, 2021

Monopar Initiates Open-Label Phase 1b Clinical Trial Evaluating Camsirubicin in Patients with Advanced Soft Tissue Sarcoma

September 15, 2021

Monopar Expands Phase 2b/3 VOICE Clinical Trial to Europe

September 12, 2021

Monopar Therapeutics to Present at Upcoming Investor Conferences in September

September 8, 2021

Monopar Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Updates

August 11, 2021

Monopar Reaches Target Number of Clinical Sites in Phase 2b Portion of 2b/3 Validive® VOICE Trial

August 4, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 7 decks. Every deck is listed under its year.